News Room
Media Contacts
1413 K Street NW, 4th Floor
Washington, D.C. 20005
Telephone: (202) 682-2640
Fax: (202) 682-2648
General Inquiries – nwhn@nwhn.org
Media Inquiries – media@nwhn.org
- FDA Takes Steps to Protect Women’s & Consumer Health over Industry ProfitsJanuary 23, 2017For Immediate Release Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225 WASHINGTON, DC — Last week, the U.S. Food and Drug Administration released a 63-page memo regarding the dissemination of information about off-label use of medical products. The memo explains that drug makers need to provide evidence of the safety and effectiveness of the medical products ...
- Health Advocates Issue One-Year Report Card on Addyi, the Female Libido DrugAugust 18, 2016FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225 WASHINGTON, DC – August 18th marks the one-year anniversary of the Food and Drug Administration’s (FDA) approval of flibanserin (brand name: Addyi), the so-called “female Viagra” pill. In light of recent developments, the National Women’s Health Network (NWHN) has issued a one-year report card. The report ...
- NWHN Applauds FDA for New Evidence Based Label Demonstrating Continued Safety & Efficacy of Medication AbortionApril 4, 2016FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at sseth@nwhn.org or 202.682-2640, ext. 225 WASHINGTON, DC — This week, the U.S. Food and Drug Administration (FDA) approved an updated, evidence-based label for mifepristone (Mifeprex®), a drug used to end an early pregnancy. The National Women’s Health Network commends the FDA for putting women’s health over politics and making this ...
- “FDA’s Actions on Essure are Steps in the Right Direction” NWHN statement in response to FDA Draft GuidanceFebruary 29, 2016FOR IMMEDIATE RELEASE Contact: Cindy Pearson at cpearson@nwhn.org or 202.682.2640, ext. 0 Safe & effective contraception, including permanent contraception, is an essential component of women’s health and economic security. Women rely on the FDA to make sure that the risks of contraceptive methods are low, and well understood. Today, the FDA took important first steps to improve women’s ...
- National Women’s Health Network Urges Women to Resist “Cheap” Gimmicks for Losing Weight in the New YearJanuary 7, 2016FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or 202.682.2640, ext 224 With the New Year often comes resolutions to lead happier – and healthier – lives. The National Women’s Health Network (“NWHN”) encourages women who have made New Year’s resolutions to lose weight to resist misleading claims about “diet drugs” and cheap gimmicks from drug companies ...
- National Women’s Health Network Condemns Violence Against Planned Parenthood Health Center in Colorado SpringsNovember 30, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or 202.682.2640, ext 224 In response to the shootings at Planned Parenthood’s health center in Colorado Springs, the National Women’s Health Network’s Executive Director, Cynthia Pearson, issued the following statement: “Every woman should be able to receive, and clinicians should be able to provide, health care services without fearing violence. Our hearts ...
- Women’s Health Leader Available for Interviews on Poor Sales of Women’s Sex Drug Addyi and Launch of New CampaignNovember 18, 2015FOR IMMEDIATE RELEASE Contact: Nora Brodnitz at nora@wcsemail.com or 202-471-0043 “PASS ON THE PINK PILL OR PASS OUT!” (Washington, D.C.) In its first month on the market, the new female libido-boosting drug Addyi (flibanserin) has seen very poor sales; just 227 women have filled prescriptions for “the pink pill” promising to boost their sex drive. Compare that to 600,000 prescriptions of ...
- New Campaign Warns Women of Harm from Drug FDA Approved in AugustNovember 17, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 Feminist Health Advocates Cite Unsafe Sex Drug for Women in Call for Next FDA Commissioner to Resist Political Pressure WASHINGTON, D.C. – As Dr. Robert Califf testifies before the Senate on his nomination for commissioner of the Food and Drug Administration, the National Women’s ...
- Warning of marginal benefits and serious side effects as drug sales beginNovember 12, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi: The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever Emergency Alert on Addyi (in four decades ...
- The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s SafetyOctober 16, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640 Washington, D.C. – Tomorrow, the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women will be available by prescription. The National Women’s Health Network (“the Network”) remains deeply concerned over the unanswered questions regarding Addyi’s interaction with alcohol and the drug’s ability to cause ...